Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:EMH CVE:KNE NYSE:MBX NASDAQ:ONC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMHEmerald Health TherapeuticsC$0.26-3.8%C$0.26C$0.15▼C$0.53C$52.28MN/A644,760 shs384,329 shsKNEKane BiotechC$0.04C$0.05C$0.04▼C$0.16C$5.76M0.5271,856 shs115,000 shsMBXMBX Biosciences$13.75+3.8%$12.25$4.81▼$27.50$459.58MN/A322,395 shs513,171 shsONCBeOne Medicines$299.01-0.7%$263.99$155.75▼$308.87$33.00B0.27402,877 shs543,060 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMHEmerald Health Therapeutics0.00%0.00%0.00%0.00%0.00%KNEKane Biotech0.00%-11.11%-27.27%-50.00%-73.33%MBXMBX Biosciences+3.77%-5.63%+11.52%+14.58%+1,374,999,900.00%ONCBeOne Medicines-0.70%+2.59%+22.38%+16.91%+29,900,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKNEKane BiotechN/AN/AN/AN/AN/AN/AN/AN/AMBXMBX Biosciences2.6288 of 5 stars3.50.00.00.03.41.70.6ONCBeOne Medicines0.7258 of 5 stars1.50.00.00.01.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMHEmerald Health Therapeutics 0.00N/AN/AN/AKNEKane Biotech 0.00N/AN/AN/AMBXMBX Biosciences 3.00Buy$37.57173.25% UpsideONCBeOne Medicines 3.00Buy$327.569.55% UpsideCurrent Analyst Ratings BreakdownLatest KNE, ONC, MBX, and EMH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$321.00 ➝ $345.007/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/16/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$311.00 ➝ $349.006/27/2025ONCBeOne MedicinesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$313.00 ➝ $330.006/27/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$317.00 ➝ $321.006/27/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$311.005/8/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$312.00 ➝ $311.005/8/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$348.00 ➝ $350.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMHEmerald Health TherapeuticsC$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64KNEKane BiotechC$1.42M4.05C$0.00 per share8.50C($0.01) per share-7.77MBXMBX BiosciencesN/AN/AN/AN/AN/AN/AONCBeOne Medicines$3.81B8.60N/AN/A$34.10 per share8.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMHEmerald Health TherapeuticsN/A-C$0.70N/A∞N/AN/AN/AN/AN/AKNEKane BiotechC$6.03MC$0.041.00∞N/A423.52%-94.49%-58.43%N/AMBXMBX BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/AONCBeOne Medicines-$644.79M-$3.72N/A421.14N/A-9.40%-7.55%-4.42%8/6/2025 (Confirmed)Latest KNE, ONC, MBX, and EMH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ONCBeOne Medicines-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AKNEKane BiotechN/A3.08%N/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMHEmerald Health Therapeutics35.452.972.61KNEKane Biotech-331.420.800.39MBXMBX BiosciencesN/AN/AN/AONCBeOne Medicines0.051.961.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMHEmerald Health TherapeuticsN/AKNEKane BiotechN/AMBXMBX BiosciencesN/AONCBeOne Medicines48.55%Insider OwnershipCompanyInsider OwnershipEMHEmerald Health TherapeuticsN/AKNEKane Biotech37.21%MBXMBX Biosciences52.19%ONCBeOne Medicines6.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMHEmerald Health Therapeutics161205.03 millionN/ANot OptionableKNEKane BiotechN/A144.06 millionN/ANot OptionableMBXMBX Biosciences3633.42 millionN/AN/AONCBeOne Medicines11,000109.60 million102.34 millionN/AKNE, ONC, MBX, and EMH HeadlinesRecent News About These CompaniesLai Wang Sells 259 Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) StockAugust 1 at 6:32 PM | marketbeat.comInsider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) SVP Sells 920 Shares of StockAugust 1 at 6:08 PM | marketbeat.comBeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Insider Lai Wang Sells 4,041 SharesAugust 1 at 6:06 PM | marketbeat.comBeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Insider Lai Wang Sells 259 SharesAugust 1 at 6:26 AM | insidertrades.comBeOne Medicines’ BTK degrader gains EMA PRIME designationAugust 1 at 4:22 AM | pharmaceutical-technology.comPBeOne Medicines (NASDAQ:ONC) Reaches New 12-Month High - Here's WhyJuly 30 at 12:39 PM | marketbeat.comEMA committee recommends approval of BeOne Medicines’ Tevimbra to treat neoadjuvant/adjuvant NSCLCJuly 30 at 11:51 AM | pharmabiz.comPBeOne Medicines' Tevimbra Gets CHMP Positive OpinionJuly 28, 2025 | marketwatch.comBeOne Medicines shares climb following positive EU backing for lung cancer therapyJuly 28, 2025 | msn.comBeOne Medicines Ltd.: BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA in Neoadjuvant/Adjuvant NSCLC TreatmentJuly 28, 2025 | finanznachrichten.deWall Street Zen Upgrades BeOne Medicines (NASDAQ:ONC) to "Buy"July 28, 2025 | americanbankingnews.comWall Street Zen Upgrades BeOne Medicines (NASDAQ:ONC) to BuyJuly 26, 2025 | marketbeat.comBeOne Medicines Ltd. (ONC) Wins EU Nod for TevimbraJuly 25, 2025 | msn.comBeOne Medicines expands R&D innovation center in BeijingJuly 25, 2025 | chinadaily.com.cnCLai Wang Sells 700 Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) StockJuly 23, 2025 | marketbeat.comBeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Insider Lai Wang Sells 700 SharesJuly 23, 2025 | insidertrades.comThe S&P 500 and Nasdaq Are Joined By These Stocks Hitting New HighsJuly 18, 2025 | msn.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for BeOne Medicines (NASDAQ:ONC) StockJuly 18, 2025 | marketbeat.comBeOne Medicines Ltd. - Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains?July 18, 2025 | zacks.comBeOne Medicines (NASDAQ:ONC) Hits New 52-Week High on Analyst UpgradeJuly 17, 2025 | marketbeat.comLooming Tariffs Don't Scare This Swiss Cancer Treatment StockJuly 16, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Is Rising Again Despite Dilution—What’s the Deal?By Nathan Reiff | July 7, 2025View D-Wave Is Rising Again Despite Dilution—What’s the Deal?Palantir Gets Price Hike From Wedbush Amid High ValuationBy Chris Markoch | July 15, 2025View Palantir Gets Price Hike From Wedbush Amid High ValuationThese 3 Dividend Stocks Are Not Concerned With Tariff NoiseBy Thomas Hughes | July 11, 2025View These 3 Dividend Stocks Are Not Concerned With Tariff NoisePEGA Surges 14%: There's Still Time to Ride This GenAI InnovatorBy Leo Miller | July 27, 2025View PEGA Surges 14%: There's Still Time to Ride This GenAI Innovator3 Retailers Poised to Outmaneuver Tariff and Recession ConcernsBy Nathan Reiff | July 20, 2025View 3 Retailers Poised to Outmaneuver Tariff and Recession ConcernsKNE, ONC, MBX, and EMH Company DescriptionsEmerald Health Therapeutics CVE:EMHC$0.26 -0.01 (-3.77%) As of 04/26/2021Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.Kane Biotech CVE:KNEC$0.04 0.00 (0.00%) As of 08/1/2025 02:17 PM EasternKane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.MBX Biosciences NYSE:MBX$13.75 +0.50 (+3.77%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$13.72 -0.03 (-0.18%) As of 08/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.BeOne Medicines NASDAQ:ONC$299.01 -2.12 (-0.70%) As of 08/1/2025 04:00 PM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
